Louisiana Medicaid does not cover Wegovy or Zepbound for weight loss

Louisiana Medicaid's pharmacy manual excludes drugs used for weight loss, except orlistat (Xenical), and the rule applies in fee-for-service and in the Healthy Louisiana managed care plans. Wegovy and Zepbound are covered only for other uses, with clinical authorization. Saxenda and Foundayo do not appear in the state's outpatient drug search. Act 898 of 2026 requires Medicaid coverage of FDA-approved weight-loss drugs, but it takes effect only once the Legislature passes a specific appropriation for it.1235101112

Louisiana Medicaid uses clinical authorization for GLP-1 drugs, with the same criteria in fee-for-service and every Healthy Louisiana plan. No criteria path covers weight loss alone.34567913

• Wegovy, cardiovascular path (criteria posted in 2024): age 45 or older, a documented BMI of 27 or more, established cardiovascular disease (prior heart attack, prior stroke, or peripheral arterial disease), no type 1 or type 2 diabetes, no other GLP-1 at the same time, and use alongside standard cardiovascular care, lifestyle counseling and a reduced-calorie diet with more physical activity. A signed treatment agreement is required to start.
• Wegovy renewals: the first approval lasts 6 months; renewal needs at least 5% weight loss from baseline, or a clinical reason it was not reached, and a maintenance dose of 1.7 mg or 2.4 mg weekly.
• Since March 1, 2026, the Wegovy criteria also include MASH (metabolic dysfunction-associated steatohepatitis).
• Zepbound: clinical authorization since January 1, 2026. LDH's April 2026 notice says the criteria cover PAP therapy and sleep study requirements, which points to sleep apnea. The full criteria are in the preferred drug list, which we could not open.
• Diabetes GLP-1s: a type 2 diabetes diagnosis and an A1C of 6.5% or more in the past 6 months, or a lower A1C with a history of 6.5% or more plus established cardiovascular disease (for Trulicity, Victoza or Ozempic). A non-preferred GLP-1 also needs a failure of, intolerance to, or contraindication to a preferred one.
• Claims for Zepbound and Wegovy tablets are rejected at the pharmacy when another GLP-1 or a DPP-4 inhibitor is active.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of cardiovascular events in adults 45 or older with a BMI of 27 or more and established cardiovascular disease, without diabetes: Covered with prior authorization34
• Wegovy (injection), MASH (metabolic dysfunction-associated steatohepatitis), added March 1, 2026: Covered with prior authorization5
• Zepbound, obstructive sleep apnea (criteria on PAP therapy and sleep studies): Covered with clinical authorization. LDH revised the criteria from January 1, 2026 "to allow clinical justification for the use of tirzepatide therapy without concurrent PAP therapy, clarified sleep study requirements".67

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Louisiana Department of Health announcement that Louisiana has joined.15

OGB's pharmacy benefit covers GLP-1 drugs only for type 2 diabetes; GLP-1s used for weight loss or weight management are not covered, and its plan documents exclude medications for obesity and weight loss. Act 749 of 2026 requires OGB to offer a separate, voluntary weight management plan from Jan. 1, 2027, with the member paying the full premium.16171819

Pharmacy benefit: Liviniti (active employees and non-Medicare retirees); SilverScript (Medicare retirees).

Marketplace (ACA) plans: Louisiana's essential health benefits benchmark plan, a Blue Cross and Blue Shield of Louisiana GroupCare PPO, excludes medications for weight loss unless the schedule of benefits shows them as covered.22

Ozempic, Mounjaro, Rybelsus, Trulicity and Victoza are payable drugs in Louisiana Medicaid's outpatient drug search. Every GLP-1, preferred or non-preferred, needs clinical authorization with a type 2 diabetes diagnosis and a recent A1C. We could not open the single preferred drug list, so which of these drugs are preferred is not shown here.910

In 2025, Louisiana Medicaid paid for 229,162 GLP-1 prescriptions, $230.3 million before rebates: 50 per 1,000 residents, against 32 across the states and DC, 9th of 51.73 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 33 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4849394035432838

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.3536372843444546474241
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.303228

In 2024, Medicare Part D drug plans paid for 498,804 GLP-1 claims from prescribers in Louisiana, $601.3 million in total drug cost.74

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.78 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Louisiana on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7980 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 0 outsourcing facilities (503B) in Louisiana, as of November 6, 2026.75